New Deep Vein Thrombosis Data Bolster Xarelto's Overall Profile
This article was originally published in The Pink Sheet Daily
A successful test as a single drug against two-step standard of care with Lovenox could help the Bayer/J&J anticoagulant stand out against its rivals.
You may also be interested in...
Bristol and Pfizer put an early end to the Phase III study successfully comparing their anticoagulant to aspirin, and the preliminary data bode well for further results due out mid-2011, but will they wait?
The attributes of Merck/Portola's Factor Xa inhibitor betrixaban, and where it fits in the crowded development space of novel anticoagulants, came into sharper focus with the release of new Phase II data at the American College of Cardiology annual meeting
Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half Along With New Application For Chronic Use
Chronic use application may help ease FDA's reluctance to make available a much anticipated and broadly applicable anticoagulant for the acute application in the original NDA.